Literature DB >> 16893427

Peptide neuroprotection through specific interaction with brain tubulin.

Inna Divinski1, Miri Holtser-Cochav, Inna Vulih-Schultzman, Ruth A Steingart, Illana Gozes.   

Abstract

This study aimed to identify the neuronal target for the potent neuroprotective peptide NAP. When added to pheochromocytoma cells (neuronal model), NAP was found in the intracellular milieu and was co-localized with microtubules. NAP induced neurite outgrowth and protected primary neurons against microtubule-associated ZnCl2 toxicity. Rapid microtubule reorganization into distinct microtubules ensued after NAP addition to both pheochromocytoma cells and primary cerebral cortical neurons, but not to fibrobalsts. While binding neuronal tubulin and protecting pheochromocytoma cells against oxidative stress, NAP did not bind tubulin extracted from fibroblasts, nor did it protect those cells against oxidative stress. Affinity chromatography identified the brain-specific betaIII-tubulin as a major NAP binding protein. Paclitaxel (a microtubule aggregating agent that interacts with beta-tubulin) reduced NAP tubulin binding. Thus, the underlying mechanism for the neuroprotection offered by NAP is targeting neuronal microtubules that are essential for neuronal survival and function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893427     DOI: 10.1111/j.1471-4159.2006.03936.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  45 in total

1.  Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases.

Authors:  Haruka Sudo; Peter W Baas
Journal:  Hum Mol Genet       Date:  2010-11-30       Impact factor: 6.150

2.  A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.

Authors:  Sheila M Fleming; Caitlin K Mulligan; Franziska Richter; Farzad Mortazavi; Vincent Lemesre; Carmen Frias; Chunni Zhu; Alistair Stewart; Illana Gozes; Bruce Morimoto; Marie-Françoise Chesselet
Journal:  Mol Cell Neurosci       Date:  2010-12-27       Impact factor: 4.314

Review 3.  Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer's Disease.

Authors:  Yanina Ivashko Pachima; Liu-yao Zhou; Peng Lei; Illana Gozes
Journal:  J Mol Neurosci       Date:  2016-02       Impact factor: 3.444

Review 4.  Neuroprotective protein and carboxypeptidase E.

Authors:  Hisatsugu Koshimizu; Vladimir Senatorov; Y Peng Loh; Illana Gozes
Journal:  J Mol Neurosci       Date:  2009-01-23       Impact factor: 3.444

5.  β-III Tubulin fragments inhibit α-synuclein accumulation in models of multiple system atrophy.

Authors:  Yasuyo Suzuki; Chenghua Jin; Tamaki Iwase; Ikuru Yazawa
Journal:  J Biol Chem       Date:  2014-07-15       Impact factor: 5.157

Review 6.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

7.  Activity-dependent neuroprotective protein-derived peptide, NAP, preventing alcohol-induced apoptosis in fetal brain of C57BL/6 mouse.

Authors:  Y Sari
Journal:  Neuroscience       Date:  2008-11-21       Impact factor: 3.590

Review 8.  New approaches to the treatment of frontotemporal lobar degeneration.

Authors:  Keith A Vossel; Bruce L Miller
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

9.  ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance.

Authors:  Shmuel Mandel; Irit Spivak-Pohis; Illana Gozes
Journal:  J Mol Neurosci       Date:  2008-02-20       Impact factor: 3.444

10.  NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42).

Authors:  Illana Gozes; Inna Divinski; Inbar Piltzer
Journal:  BMC Neurosci       Date:  2008-12-10       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.